How lasting blood vessel damage in the brain after head injury may lead to memory loss
Mechanisms of Chronic Blood-Brain Barrier Dysfunction after Traumatic Brain Injury
This project will see if blocking a specific inflammation pathway (RIPK1–RIPK3–IL‑1) can prevent long-term blood–brain barrier damage and protect thinking and memory after a serious head injury.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11252597 on NIH RePORTER |
What this research studies
You will read about laboratory research that explores why blood vessels in the brain remain damaged months after a traumatic brain injury (TBI). The team uses mouse models of controlled head injury and compares normal animals to ones engineered or treated to block the RIPK1–RIPK3–IL‑1 inflammation pathway. They deliver genetic and viral tools to brain blood vessel cells, then measure blood–brain barrier leakage, vessel density, inflammation, and cognitive performance over time. The goal is to find whether stopping this pathway reduces chronic vessel damage that can lead to dementia.
Who could benefit from this research
Good fit: People who have had a moderate to severe traumatic brain injury and are at risk for long-term cognitive decline would be the most relevant future candidates.
Not a fit: Patients whose dementia is driven primarily by non-vascular genetic causes or who had only a very mild, remote head injury may not see direct benefit from this approach.
Why it matters
Potential benefit: If successful, this work could point to new treatments that protect brain blood vessels after TBI and lower the risk of later memory loss or dementia.
How similar studies have performed: Prior animal studies, including the team's preliminary mouse data, suggest blocking RIPK1/RIPK3 or inflammasome pathways can reduce BBB damage, but translating these findings into human treatments has not yet been demonstrated.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Whalen, Michael J — Massachusetts General Hospital
- Study coordinator: Whalen, Michael J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.